PW Medtech Group Limited (stock code: 1358), a leading medical device company in China, today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited. PW Medtech plans to offer an aggregate of 400,000,000 shares to raise net proceeds of approximately HK$1,118.5 million.

PW Medtech is a leading medical device company in China focused on high-growth, high-margin and large market capacity segments in the medical device industry. The core business of the Group is orthopedic implants and advanced infusion sets, which are both at the forefront of the China medical market. 

The Group has delivered strong financial performance with the orthopedic implants and infusion sets businesses. Its revenue grew to RMB331.5 million in 2012, or at a CAGR of 133.5% from 2010 to 2012. Net profit grew to RMB100.2 million in 2012, representing a CAGR of 164.4% from 2010 to 2012. Total revenue increased by 50.1% from RMB145.8 million in the six months ended June 30, 2012 to RMB218.8 million in the same period in 2013, reflecting an increase in revenue from both the orthopedic implant and infusion set businesses.